Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors
Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumor malignancies, today announced it has raised $120 million in an oversubscribed and upsized financing to accelerate the development of its clinical pipeline and proprietary CloakLink™ linker platform.
